ArticleJournal of translational medicine2026
Varenicline-mediated cholinergic activation through α4β2 nAChR inhibits microglial neuroinflammation and alleviates neuropathic pain and depression following spinal cord injury.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpinal cord injury (SCI) often leads to neuropathic pain. Chronic pain is frequently comorbid with depression and is often refractory, becoming a focal point in clinical and basic research. Neuroprotective pathways activated by nicotinic acetylcholine receptors (nAChRs) are attractive therapeutic targets for neurodegenerative diseases. The α4β2 nAChR agonist varenicline has been shown to alleviate pain, reduce functional disability, and improve cognitive aspects; however, understanding of its effects and mechanisms on neuropathic pain following SCI remains limited. PURPOSE: We hypothesize that varenicline regulates cholinergic activity in microglia by activating α4β2 nAChRs, thereby inhibiting neuroinflammation. We aimed to elucidate this mechanism to provide new therapeutic strategies for alleviating comorbid neuropathic pain and depression following SCI.
methodsWe used a rat T3 spinal cord compression injury model. Behavioural assessments, immunofluorescence, and transcriptomics were employed to investigate the effects of varenicline on mechanical and cold hypersensitivity as well as changes in negative mood in T3-SCI model rats. We analysed the expression of sensory afferent neurons and cholinergic neurons in the dorsal horn of the spinal cord among the different treatment groups. Additionally, we assessed the impact of varenicline on neuroinflammation and nAChRs following SCI.
resultsFollowing T3-SCI, the expression of nAChRs, including acetylcholine (ACh) neurotransmitter vesicles, ACh transporters, ACh metabolism enzymes, α4β2 nAChRs, and α7 nAChRs, and cholinergic activity were significantly suppressed, accompanied by an increase in microglia-dominated neuroinflammation. Varenicline pretreatment significantly enhanced impaired cholinergic neurotransmission and α4β2 nAChR expression following SCI; furthermore, it simultaneously inhibited the widespread activation and proliferation of microglia/macrophage-mediated neuroinflammation. Varenicline suppressed the sprouting of calcitonin gene-related peptide afferent fibres in the dorsal horn of the spinal cord after SCI. Additionally, varenicline reduced pain hypersensitivity and negative emotional aspects of depression following SCI. Varenicline also improved the Th1/Th2 immune balance after SCI.
conclusionVarenicline can activate α4β2 nAChRs on neurons and enhance cholinergic activity after SCI. It is also associated with a significant suppression of widespread microglia-mediated neuroinflammation and the promotion of immune balance between Th1 and Th2 cells following injury. Moreover, varenicline appears to alleviate neuropathic pain and the negative emotional components of depression after SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.